DE60140860D1 - 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren - Google Patents

2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren

Info

Publication number
DE60140860D1
DE60140860D1 DE60140860T DE60140860T DE60140860D1 DE 60140860 D1 DE60140860 D1 DE 60140860D1 DE 60140860 T DE60140860 T DE 60140860T DE 60140860 T DE60140860 T DE 60140860T DE 60140860 D1 DE60140860 D1 DE 60140860D1
Authority
DE
Germany
Prior art keywords
group
mono
tyrosine kinase
receptor tyrosine
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140860T
Other languages
English (en)
Inventor
Paul William Manley
Guido Bold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60140860D1 publication Critical patent/DE60140860D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60140860T 2000-01-27 2001-01-25 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren Expired - Lifetime DE60140860D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001930.7A GB0001930D0 (en) 2000-01-27 2000-01-27 Organic compounds
PCT/EP2001/000835 WO2001055114A1 (en) 2000-01-27 2001-01-25 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
DE60140860D1 true DE60140860D1 (de) 2010-02-04

Family

ID=9884488

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60140860T Expired - Lifetime DE60140860D1 (de) 2000-01-27 2001-01-25 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren

Country Status (25)

Country Link
US (1) US6624174B2 (de)
EP (2) EP1259487B8 (de)
JP (1) JP3894793B2 (de)
KR (1) KR100554988B1 (de)
CN (1) CN1216867C (de)
AT (1) ATE452880T1 (de)
AU (1) AU771626B2 (de)
BR (1) BR0107805A (de)
CA (1) CA2396590C (de)
CZ (1) CZ20022582A3 (de)
DE (1) DE60140860D1 (de)
ES (2) ES2490191T3 (de)
GB (1) GB0001930D0 (de)
HK (1) HK1050895A1 (de)
HU (1) HUP0204083A3 (de)
IL (2) IL150481A0 (de)
MX (1) MXPA02007319A (de)
NO (1) NO323826B1 (de)
NZ (1) NZ520005A (de)
PL (1) PL356307A1 (de)
PT (2) PT1259487E (de)
RU (1) RU2296124C2 (de)
SK (1) SK287426B6 (de)
WO (1) WO2001055114A1 (de)
ZA (1) ZA200205988B (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US7419428B2 (en) * 2000-04-28 2008-09-02 Igt Cashless transaction clearinghouse
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
BRPI0113757B1 (pt) 2000-09-11 2017-05-23 Chiron Corp derivados de quinolinona como inibibores de tirosina quinase
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL158783A0 (en) * 2001-05-08 2004-05-12 Schering Ag Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
CA2493026C (en) * 2002-07-31 2011-05-24 Schering Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
EP2573079A3 (de) 2002-08-23 2015-03-11 Novartis AG Benzimidazolchinolinonderivate und ihre Verwendung
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
US7534802B2 (en) 2003-03-07 2009-05-19 Santen Pharmaceutical Co., Ltd. Compounds having 4-pyridylalkylthio group as substituent
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
CN1856326A (zh) * 2003-09-23 2006-11-01 诺瓦提斯公司 Vegf受体抑制剂与其它治疗剂的组合
KR20060097000A (ko) * 2003-09-23 2006-09-13 노파르티스 아게 화학요법제와 ｖｅｇｆ 수용체 저해제의 배합물
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
CA2544186A1 (en) 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma with benzimidazole quinolinones
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
NZ548949A (en) 2004-02-17 2009-09-25 Santen Pharmaceutical Co Ltd Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US7507748B2 (en) * 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
EP1657241A1 (de) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Neue Antranilamidpyrdinharnstoffe mit hemmender Wirkung auf VEGF-Rezeptor Kinase
EP1655295A1 (de) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamid-Pyridinharnstoffe als VEGF Rezeptor Kinase Inhibitoren
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
JPWO2006070878A1 (ja) * 2004-12-28 2008-06-12 アステラス製薬株式会社 カルボン酸誘導体またはその塩
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
EP1844136B1 (de) 2004-12-29 2014-08-27 Hadasit Medical Research Services And Development Ltd. Stammzellenkultursysteme
WO2006093253A1 (ja) * 2005-03-03 2006-09-08 Santen Pharmaceutical Co., Ltd. キノリルアルキルチオ基を有する新規環式化合物
ES2548729T3 (es) 2005-03-31 2015-10-20 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio
WO2006125130A1 (en) 2005-05-17 2006-11-23 Novartis Ag Methods for synthesizing heterocyclic compounds
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
PT1957074E (pt) 2005-11-29 2014-06-25 Novartis Ag Formulações de quinolinonas
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
US8063034B2 (en) 2007-01-29 2011-11-22 Santen Pharmaceutical Co., Ltd. Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
EP3640326A1 (de) 2007-04-18 2020-04-22 Hadasit Medical Research Services & Development Limited Aus stammzellen erhaltene retinale pigmentepithelzellen
BRPI0907121A2 (pt) * 2008-01-07 2015-07-14 Ortho Clinical Diagnostics Inc Calibrador/controle para ensaio simultâneo de proteínas capazes de se complexarem mutuamente
MX338088B (es) * 2008-03-26 2016-04-01 Novartis Ag Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
EP2346827B1 (de) * 2008-08-27 2013-11-13 Leo Pharma A/S Pyridinderivate als inhibitoren des vegfr-2-rezeptors und der proteintyrosinkinase
CN101676267B (zh) * 2008-09-16 2012-12-26 江苏恒瑞医药股份有限公司 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
CA2773661A1 (en) 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
SI2485731T1 (sl) * 2009-10-06 2016-09-30 Millennium Pharmaceuticals, Inc. Heterociklične spojine, ki se uporabljajo kot inhibitorji pdk1
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
KR101412794B1 (ko) * 2011-07-27 2014-07-01 보령제약 주식회사 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
CA2871651A1 (en) * 2012-05-08 2013-11-14 Anvyl Llc Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
ES2711882T3 (es) * 2013-11-28 2019-05-08 B Creative Sweden Ab Método de tratamiento de la nefropatía diabética
RU2713179C2 (ru) 2014-02-21 2020-02-04 Фрост Биолоджик, Инк. Антимитотические амиды для лечения рака и пролиферативных заболеваний
DK3240892T5 (da) 2014-12-30 2020-10-19 Cell Cure Neurosciences Ltd Rpe-cellepopulationer og fremgangsmåder til dannelse deraf
EP3240890B1 (de) 2014-12-30 2021-06-16 Cell Cure Neurosciences Ltd. Beurteilung von netzhautpigmentepithelzellpopulationen
ES2865024T3 (es) 2015-07-29 2021-10-14 Hadasit Med Res Service Producción a gran escala de células de epitelio pigmentario retiniano
AU2016303631B2 (en) 2015-08-05 2022-07-28 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
EA201890424A1 (ru) 2015-08-05 2018-06-29 Селл Кьюр Нейросайансес Лтд. Получение клеток пигментного эпителия сетчатки
AU2016317806B2 (en) 2015-08-31 2020-11-19 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as therapeutic drugs
CA3002919A1 (en) 2015-10-26 2017-05-04 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
KR20200031559A (ko) 2017-03-16 2020-03-24 리니지 셀 테라퓨틱스, 인크. 망막 질환 요법의 치료 효과를 측정하는 방법
CA3079076A1 (en) 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
WO2019119486A1 (zh) 2017-12-21 2019-06-27 中国科学院合肥物质科学研究院 一类嘧啶类衍生物激酶抑制剂
CN113038951B (zh) 2018-09-20 2024-04-30 耶达研究及发展有限公司 治疗肌萎缩侧索硬化的方法
EP3754014A1 (de) 2019-06-21 2020-12-23 Centre d'Etude des Cellules Souches (CECS) Automatisiertes verfahren zur herstellung von retinalen pigmentepithelzellen
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
WO2022261320A1 (en) 2021-06-09 2022-12-15 Lineage Cell Therapeutics, Inc. Methods and compositions for treating retinal diseases and conditions
KR20240038013A (ko) 2021-07-28 2024-03-22 리니지 셀 테라퓨틱스, 인크. 망막 색소 상피 세포의 확장
WO2023211857A1 (en) 2022-04-25 2023-11-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating vision loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0393529T3 (da) 1989-04-20 1993-11-15 Boehringer Ingelheim Pharma 5,11-Dihydro-6H-dipyrido(3,2-b:2,3-e)(1,4)diazepin-6-oner og deres anvendelse ved forhindring eller behandling af AIDS
AU720429B2 (en) 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
ID22781A (id) 1997-04-04 1999-12-09 Pfizer Prod Inc Turunan-turunan nikotinamida
WO1998057957A1 (fr) 1997-06-18 1998-12-23 Nissan Chemical Industries, Ltd. Composes pyridiniques et herbicides associes
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
US6506747B1 (en) 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
AU2054700A (en) 1998-12-23 2000-07-31 Eli Lilly And Company Antithrombotic amides
JP3989175B2 (ja) * 1999-04-15 2007-10-10 ブリストル−マイヤーズ スクイブ カンパニー 環状タンパク質チロシンキナーゼ阻害剤
WO2001055115A1 (en) 2000-01-27 2001-08-02 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof

Also Published As

Publication number Publication date
NO20023218D0 (no) 2002-07-02
CN1216867C (zh) 2005-08-31
GB0001930D0 (en) 2000-03-22
NO20023218L (no) 2002-09-16
MXPA02007319A (es) 2002-11-29
AU2849901A (en) 2001-08-07
EP2168948A1 (de) 2010-03-31
CA2396590C (en) 2011-03-01
US20030032656A1 (en) 2003-02-13
SK10852002A3 (sk) 2003-05-02
NZ520005A (en) 2004-02-27
NO323826B1 (no) 2007-07-09
EP2168948B1 (de) 2014-05-07
CN1396912A (zh) 2003-02-12
HK1050895A1 (en) 2003-07-11
PL356307A1 (en) 2004-06-28
HUP0204083A2 (hu) 2003-03-28
HUP0204083A3 (en) 2005-03-29
EP1259487B8 (de) 2014-04-23
KR100554988B1 (ko) 2006-02-24
CA2396590A1 (en) 2001-08-02
PT1259487E (pt) 2010-03-26
ES2338407T3 (es) 2010-05-07
RU2296124C2 (ru) 2007-03-27
ZA200205988B (en) 2003-07-28
ES2490191T3 (es) 2014-09-03
US6624174B2 (en) 2003-09-23
PT2168948E (pt) 2014-08-26
WO2001055114A1 (en) 2001-08-02
IL150481A0 (en) 2002-12-01
EP1259487B1 (de) 2009-12-23
EP1259487A1 (de) 2002-11-27
IL150481A (en) 2009-09-22
KR20020071973A (ko) 2002-09-13
CZ20022582A3 (cs) 2002-10-16
AU771626B2 (en) 2004-04-01
BR0107805A (pt) 2002-10-22
SK287426B6 (sk) 2010-09-07
JP3894793B2 (ja) 2007-03-22
ATE452880T1 (de) 2010-01-15
JP2003520853A (ja) 2003-07-08

Similar Documents

Publication Publication Date Title
DE60140860D1 (de) 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren
ATE180468T1 (de) Anthranilsäure derivate
MX2007006821A (es) Derivados de 2,4 (4,6) pirimidina.
DE69428476D1 (de) Heterocyclische Verbindungen als Bradykinin Antagonisten
DE69614147D1 (de) Chinazolin-derivate
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
ATE496035T1 (de) Stickstoffenthaltende heterocyclische verbindungen
ATE274512T1 (de) Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
EP1396493A4 (de) Heterocyclische verbindungen
DE60115465D1 (de) Immunoregulierende verbindungen, deren derivate und ihre verwendung
EA200601235A1 (ru) Производные тиазола
DE3781080D1 (de) 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
TR200103789T2 (tr) Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller.
PT1315730E (pt) Derivados de 1-[alquil],1-[(heteroaril)-alquil] e 1-[(aril)-alquil]-7-piridinil-imidazo[1,2-a]pirimidin-5(1h)-ona
DK0780125T3 (da) Anvendelse af hydantoinderivater til fremstilling af et lægemiddel til behandling af sygdomme associeret med tilstedeværelse af aktivt oxygen og frie radikaler
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
DE69720966D1 (de) Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
EA199800720A1 (ru) Гетероциклические производные эрголина в качестве лигандов 5-htia рецептора
CA2385244A1 (en) Novel nicotinonitrile compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN